M/M
10-27-2020, 07:33 AM
Good clues that digital ID chips and transhumanist agenda may be the real priorities:
How COVID-19 Vaccine Trials Are Rigged
https://articles.mercola.com/sites/articles/archive/2020/10/27/covid-vaccine-trials.aspx?cid_source=dnl&cid_medium=email&cid_content=art1ReadMore&cid=20201027Z1&mid=DM692979&rid=997453298
While vaccine makers insist any COVID-19 vaccine reaching the market will have undergone rigorous testing, the way trial protocols are designed suggests these vaccines will not have a significant impact on infection rates, hospitalizations or deaths
Shockingly, preventing infection with SARS-CoV-2 is not a criterion for success in these vaccine trials. The only criterion for a successful COVID-19 vaccine is a reduction of symptoms shared by both COVID-19 and the common cold
In AstraZeneca’s case, the interim analysis includes 50 vaccine recipients. The vaccine will be a success if 12 or fewer develop symptoms after exposure to SARS-CoV-2, compared to 19 in the 25-person control group
At least two cases of transverse myelitis (severe inflammation of the spinal cord) has been documented in AstraZeneca’s trial, and the company temporarily halted its trial in September 2020. In October, Johnson & Johnson also paused its trial due to an undisclosed “unexplained illness” in one of its participants
If the vaccine cannot reduce infection, hospitalization or death, then it cannot end the pandemic, which means everyone who takes the vaccine will be doing so in vain
How COVID-19 Vaccine Trials Are Rigged
https://articles.mercola.com/sites/articles/archive/2020/10/27/covid-vaccine-trials.aspx?cid_source=dnl&cid_medium=email&cid_content=art1ReadMore&cid=20201027Z1&mid=DM692979&rid=997453298
While vaccine makers insist any COVID-19 vaccine reaching the market will have undergone rigorous testing, the way trial protocols are designed suggests these vaccines will not have a significant impact on infection rates, hospitalizations or deaths
Shockingly, preventing infection with SARS-CoV-2 is not a criterion for success in these vaccine trials. The only criterion for a successful COVID-19 vaccine is a reduction of symptoms shared by both COVID-19 and the common cold
In AstraZeneca’s case, the interim analysis includes 50 vaccine recipients. The vaccine will be a success if 12 or fewer develop symptoms after exposure to SARS-CoV-2, compared to 19 in the 25-person control group
At least two cases of transverse myelitis (severe inflammation of the spinal cord) has been documented in AstraZeneca’s trial, and the company temporarily halted its trial in September 2020. In October, Johnson & Johnson also paused its trial due to an undisclosed “unexplained illness” in one of its participants
If the vaccine cannot reduce infection, hospitalization or death, then it cannot end the pandemic, which means everyone who takes the vaccine will be doing so in vain